Form 4: Lilly Endowment Inc. Sells 1,441 Shares of Eli Lilly & Co.

Lilly Endowment Inc. sold 1,441 shares of Eli Lilly & Co. at a weighted average price of $915.021 per share on June 28, 2024.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold 1,441 shares of common stock.
• The transaction occurred on June 28, 2024.
• The shares were sold at a weighted average price of $915.021.
• The sale was executed in multiple transactions with prices ranging from $915.00 to $915.185 per share.
• Following the transaction, Lilly Endowment Inc. beneficially owns 97,367,369 shares of Eli Lilly & Co.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a share sale, which is neither positive nor negative in itself. It's a neutral event from an investment perspective.

Management Comments

• Ben W. Blanton, Vice President, Secretary & General Counsel, signed the Form 4 on behalf of Lilly Endowment Inc.

Industry Context

This transaction is a routine disclosure of a significant shareholder's trading activity and is typical for large institutional investors. It does not necessarily indicate a change in the company's outlook or performance.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The transaction size is relatively small compared to the total holdings of Lilly Endowment Inc., which is a common occurrence for large institutional investors who may rebalance their portfolios.

Stakeholder Impact

• The sale of shares by Lilly Endowment Inc. may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, Form 4